Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The FDA aims to make a decision by April 8, 2026
The companies aim to expand treatment options for millions living with metabolic disorders
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
Subscribe To Our Newsletter & Stay Updated